CAM
CRBP icon

ClariVest Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

ClariVest Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$725K Hold
16,021
– – 0.07% 313
2024
Q2 		$725K Buy
+16,021
New +$674K 0.07% 313

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

ClariVest Asset Management's CRBP Position: Q3 2024 in Review

ClariVest Asset Management held its Corbus Pharmaceuticals (CRBP) position steady in Q3 2024 at 16,021 shares worth $725K. The position accounts for 0.07% of the portfolio, ranked #313.

ClariVest Asset Management first reported a position in CRBP in Q2 2024 and has held it in 2 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • ClariVest Asset Management held 16,021 shares of Corbus Pharmaceuticals worth $725K as of Q3 2024.
  • ClariVest Asset Management left its Corbus Pharmaceuticals share count unchanged in Q3 2024.
  • Corbus Pharmaceuticals made up 0.07% of ClariVest Asset Management's portfolio in Q3 2024, its #313 holding.
  • ClariVest Asset Management first reported a position in Corbus Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.